Asian journal of urology · 2025
Exploring the role of urinary brain-derived neurotrophic factor in diagnosis and follow-up of overactive bladder in women: A prospective analytical study in a tertiary care center experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hussein Hussein Aly, Sheba Mostafa, Shams El Din Aly Ahmed, Tawfik Mohamed, Morsy Samer
Аннотация
OBJECTIVE: Overactive bladder (OAB) is a common clinical manifestation of voiding dysfunction. It is a symptom-based condition. A new, accurate, objective, and noninvasive test to diagnose OAB and assess therapeutic outcomes is lacking. The study aimed to assess the use of the urinary biomarker brain-derived neurotrophic factor (BDNF), as a non-invasive diagnostic and follow-up tool.
METHODS: This prospective analytical study was conducted in the Department of Urology, Cairo University Hospitals. A total of 96 women were included in the study and distributed into two groups: Group A with OAB (n=48) and Group B (control group, n=48).
RESULTS: The mean urinary BDNF/creatinine ratio in the OAB group was 15.2 (standard deviation [SD] 5.9) pg/mg, ranging from 5.1 to 24.2 pg/mg, whereas the mean urinary BDNF/creatinine ratio in the control group was 5.6 (SD 2.7) pg/mg, ranging from 1.1 to 10.0 pg/mg, with a statistically significant difference between the groups (independent samples t-test, p<0.001). Following a 3-month treatment period with solifenacin, a statistically significant reduction was found in the urinary BDNF/creatinine ratio of the OAB group to a mean of 8.2 (SD 3.7) pg/mg, ranging from 2.2 to 14.7 pg/mg (paired samples t-test, p<0.001).
CONCLUSION: BDNF can be used to assess the presence of OAB and follow up the course of OAB as a supplementary tool to clinical assessment and urodynamics.
METHODS: This prospective analytical study was conducted in the Department of Urology, Cairo University Hospitals. A total of 96 women were included in the study and distributed into two groups: Group A with OAB (n=48) and Group B (control group, n=48).
RESULTS: The mean urinary BDNF/creatinine ratio in the OAB group was 15.2 (standard deviation [SD] 5.9) pg/mg, ranging from 5.1 to 24.2 pg/mg, whereas the mean urinary BDNF/creatinine ratio in the control group was 5.6 (SD 2.7) pg/mg, ranging from 1.1 to 10.0 pg/mg, with a statistically significant difference between the groups (independent samples t-test, p<0.001). Following a 3-month treatment period with solifenacin, a statistically significant reduction was found in the urinary BDNF/creatinine ratio of the OAB group to a mean of 8.2 (SD 3.7) pg/mg, ranging from 2.2 to 14.7 pg/mg (paired samples t-test, p<0.001).
CONCLUSION: BDNF can be used to assess the presence of OAB and follow up the course of OAB as a supplementary tool to clinical assessment and urodynamics.